Acino is a Swiss-based pharmaceutical company which was founded in 1836 and develops, manufactures and internationally markets well-proven and innovative pharmaceuticals in novel drug delivery forms.

Acino is a leader in advanced drug delivery technologies specialising in modified release oral forms and oral dispersible forms for which it also holds patents. As a partner of pharmaceutical companies worldwide, Acino supplies finished in-house developed products and/or provides customised one-stop solutions from product development and registration to contract manufacturing, packaging and logistics. Under the brand "Acino Switzerland", Acino markets Swiss-quality medicines in fast-growing emerging economies in the Middle East, Africa, Ukraine and the CIS Region (Commonwealth of Independent States) including Russia, and Latin America.


On December 12, 2013, Pharma Strategy Partners GmbH, an indirect subsidiary of Nordic Capital Fund VII and its co-investor Avista Capital Partners, successfully completed its public tender offer for Acino Holding AG. The Acino shares was consequently delisted from the stock exchange. Nordic Capital acquired Acino due to its unique combination of local footprint and Swiss origin, with the aim to further grow the company through selective add-on acquisitions and in-licensing deals.

Key Information

Revenues Icon

Revenues 2017*

EUR 300 million

Employees Icon



Ownership Icon


Nordic Capital Fund VII

Head Office Icon

Head office

Zurich, Switzerland

Investment Icon

Investment date


* Reported